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Abstract
Background: The LIFE-Adult-Study is a population-based cohort study, which has recently completed the baseline
examination of 10,000 randomly selected participants from Leipzig, a major city with 550,000 inhabitants in the east
of Germany. It is the first study of this kind and size in an urban population in the eastern part of Germany. The
study is conducted by the Leipzig Research Centre for Civilization Diseases (LIFE). Our objective is to investigate
prevalences, early onset markers, genetic predispositions, and the role of lifestyle factors of major civilization diseases,
with primary focus on metabolic and vascular diseases, heart function, cognitive impairment, brain function,
depression, sleep disorders and vigilance dysregulation, retinal and optic nerve degeneration, and allergies.
Methods/design: The study covers a main age range from 40-79 years with particular deep phenotyping in elderly
participants above the age of 60. The baseline examination was conducted from August 2011 to November 2014. All
participants underwent an extensive core assessment programme (5-6 h) including structured interviews, questionnaires,
physical examinations, and biospecimen collection. Participants over 60 underwent two additional assessment
programmes (3-4 h each) on two separate visits including deeper cognitive testing, brain magnetic resonance
imaging, diagnostic interviews for depression, and electroencephalography.
Discussion: The participation rate was 33 %. The assessment programme was accepted well and completely passed by
almost all participants. Biomarker analyses have already been performed in all participants. Genotype, transcriptome and
metabolome analyses have been conducted in subgroups. The first follow-up examination will commence in 2016.
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Background
Since the German reunification in 1990, East Germany
has experienced profound social and lifestyle changes.
Large efforts have been undertaken to equalize the pre-
vious disparities of living conditions between East and
West Germany. Remarkably, the disparities of life ex-
pectancy of about 2-3 years observed in the 1990s have
vanished within 20 years [1]. However, differences in
health related aspects still exist. Standardized mortality
rates due to cardiovascular diseases are still high in the
east German states of Saxony-Anhalt, Mecklenburg-
Western Pomerania, and Saxony. The prevalence of psy-
chiatric disorders is increasing both in the western and
eastern part of Germany, however, at a faster rate in the
east. The eastern states of Germany also face a progressive
demographic change. Therefore, disease prevention
programmes and predictions of disease developments are
urgently needed by various stakeholders in the German
health care system.
Population-based cohort studies are a vital means to in-
vestigate the interactions of predisposing genetic, environ-
mental, social and lifestyle factors with health maintenance
and disease onset. Several population-based studies have
been conducted in other areas of Germany in the past de-
cades focusing on a limited set of phenotypes and specific
diseases [2–6]. In 2009, the Leipzig Research Centre for
Civilization Diseases (LIFE) was initiated within the highly
competitive intitiative for excellence in research of the Free
State of Saxony. LIFE is part of the Medical Faculty of the
University of Leipzig, enabling participation of clinical and
epidemiological researchers experienced in the field of
metabolic, neurological, cardiovascular, allergological and
ophthalmological disorders, and of methodological re-
searchers experienced in molecular and genetic profiling,
biostatistics and bioinformatics. In addition, researchers of
the Leipzig Heart Centre and the Max Planck Institute for
Human Cognitive and Brain Sciences Leipzig, two major
medical research institutions in the city, are involved in the
LIFE-Adult-Study.
Leipzig is a city with approximately 550,000 inhabitants
of mostly central European descent. The LIFE-Adult-
Study pursues the following major goals: i) to assess the
prevalence and incidence of common diseases and sub-
clinical disease phenotypes, ii) to investigate the complex
interactions between molecular-genetic and lifestyles fac-
tors regarding co-occurrence and development of subclin-
ical phenotypes and diseases, and iii) to investigate in a
longitudinal extension of the study the role of biomarkers
to predict risks for disease progression. In particular, we
focus on the following mostly age-related clinical pheno-
types: metabolic disorders (type 2 diabetes, hyperlipopro-
teinemia, obesity), cardiovascular disorders and heart
failure, cognition and brain function, depression, sleep
disorders and vigilance regulation, early signs of retinal
and optic nerve degeneration, and allergies (Table 1). We
introduced several innovative assessment techniques in
order to investigate novel phenotypes, e.g. optical coher-
ence tomography (OCT) of the retina, 3D body surface
scans, EEG-based recording of vigilance regulation, sleep
duration, voice function. This is accompanied by analyses
of more than 80 clinical chemical biomarkers, and compre-
hensive molecular-genetic profiling comprising genotyping,
transcriptome, metabolome, and proteome analyses.
The study was designed in 2008. Funding was available
in August 2009. Positive ethics votes were obtained in
2010. Feasibility studies for several assessments started late
in 2010. A pilot study to optimize the full programme was
conducted early in 2011, when the biorepository and the
IT-infrastructure was established. A comprehensive set of
standard operating procedures (SOP) was implemented.
Recruitment started in August 2011. In November 2014
the recruitment of the cohort was successfully completed.
This paper describes the objectives and the design of the
LIFE-Adult-Study. We also present first results regarding
the recruitment, response rates, and conduct of the study.
Methods/Design
Study population and recruitment
The study design comprised an age and gender stratified
random sample of residents of the city of Leipzig, in the
age group of 40 to 79 years. A subset of 400 participants
aged 18 to 39 years was also recruited. In total, 10,000 par-
ticipants were planned as the target population (Fig. 1).
Address lists of randomly sampled citizens were provided
by the resident’s registration office of the city of Leipzig.
Citizens were sent an invitation letter containing an infor-
mation leaflet about the study, a response form and a
postage-paid return envelope. Persons who did not
respond within four weeks received a reminder letter.
Non-responders were searched in public telephone
directories and contacted by phone. Persons who were in-
terested to participate were scheduled for an appointment
in the LIFE study centre. As a prerequisite to enrolment,
written informed consent was obtained from all par-
ticipants. The study was approved by the responsible ins-
titutional ethics board of the Medical Faculty of the
University of Leipzig. The data privacy and safety concept
of the study was approved by the responsible data protec-
tion officer. Possible incidents during study visits and
during travel to the study site were covered by an insur-
ance policy. Participants received a lump sum of 20 EUR
per visit to cover their travel expenses. No other financial
incentives were paid out. We carried out several public
relation activities to stimulate participation rates. The
LIFE study centre was located on the medical campus in
the centre of the city, which was easy to reach.
In March 2013, we decided to modify the inclusion
criteria of the programme with a reduction of the upper
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age limit to 74 years. We observed that participants
aged ≥75 years had difficulties in completing the assess-
ment programme within the set time limit despite high
motivation. Furthermore, it became apparent that
participation of women in this age group was markedly
reduced (about 1/3 lower than men). The most fre-
quently given reason was that women would not leave
their diseased and care-needing partners alone at home
on three study days. Therefore, as we stopped recruit-
ment of participants ≥75 years, we extended the lower
age limit for deep cognition and depression phenotyping
to 60 years. This change was put in place in March 2013
after approval by the institutional ethics board.
In a subset of participants we investigated whether
body fat distribution is associated with functional traits
of the brain (magnetic resonance imaging, MRI) and
traits of eating behaviour. To unravel this question a
subcohort of 1200 participants aged 18-79 underwent
abdominal MRI-scans in addition to brain MRI-scans.
Disclosure of results and pathological findings to
participants
Participants were offered to be informed about selected
examination results. If they agreed, they received a letter
within two weeks of the study visit comprising their la-
boratory and anthropometric data, blood pressure, intima
media thickness, ankle-brachial index, and the results of
the skin prick test. Participants were informed about
pathological findings according to a pre-defined protocol
using four categories of severity (very high: acute life-
threatening condition requiring immediate intervention,
high: not acute life-threatening condition needing imme-
diate medical clarification or treatment, medium: need for
near-term medical clarification, low: recommendation of
medical supervision, e.g. by a general practitioner).
Data management
We developed and set up a comprehensive dedicated IT
infrastructure to support processes such as recruiting,
appointment scheduling, assessment coordination, data
entry, data integration, pre-processing, quality control,
data curation and analysis. The infrastructure consists of
several commercial and self-developed software systems
running in a shared network. An ORACLE® database
(Oracle Corporation, Redwood Shores, CA, USA) is used
for storing administrative and most assessment data. A
tailor-made participant management system was used to
Fig. 1 Target sample sizes of the LIFE-Adult-Study
Table 1 Major diseases and phenotypes investigated in the
LIFE-Adult-Study
● Cardiovascular diseases (myocardial infarction, heart failure,
atherosclerosis, cardiac arrhythmias)
● Metabolic diseases (obesity, type 2 diabetes)
● Cognition and brain functioning
● Depression (including minor depression)
● Sleep disorders and vigilance regulation
● Degenerative diseases of the retina
● Allergies and immune competence
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organise participant data (e.g. subject identity, pseudony-
misation, and appointments) separately from the scientific
data. LimeSurvey® (www.limesurvey.org) and TeleForm®
(Electric Paper Informationssysteme GmbH, Lüneburg,
Germany) were used to collect data from interviews, ques-
tionnaires and examinations via PC-based or paper-based
data capture, respectively. Dedicated IT processes were
put in place to collect image and biosignal data from
measurement devices wherever possible. All biospecimen
related processes (e.g. collection, labelling, processing,
aliquoting, distribution, storage) were administered using
a self-developed laboratory information system (LIMS) -
CryoLab. Data and analysis results were integrated into a
comprehensive research database. We used the ‘LIFE
Investigation Ontology’ (LIO) to semantically describe,
classify and retrieve data in the research database [7].
Biobanking
A novel semi-automated cryobiobank with continuous
cooling chains warrants sustainability for later bioanaly-
tics. In the LIFE-Adult-Study, biospecimen of stabilized
(Tempus, life technologies) and unstabilized whole blood
(EDTA-blood), dried blood spot cards, serum, plasma
(EDTA, citrate, lithium heparine), urine, peripheral
blood mononuclear cells (PBMC), DNA and RNA sam-
ples were collected and stored according to SOPs. 50
different aliquots were cloned within 2 h of blood sam-
pling and stored at -80 °C (DNA, RNA, EDTA-blood,
urine, serum) or at temperatures below -150 °C (serum,
plasma, PBMCs) in the gas phase of liquid nitrogen.
Prior to storage, samples were processed and cloned in
barcode labelled cryotubes and straws. To minimize
freeze-thaw cycles, samples were sorted in a cryogenic
work bench (temperatures below -100 °C) and automat-
ically stored in tanks with a coolable top frame in the
gas phase of liquid nitrogen (Askion, Germany).
Quality management
Prior to the study, several assessments were tested in
feasibility studies in order to evaluate their practicability,
time requirements, inter- and intra-observer reliability,
and validity [8–10]. The entire assessment programme
was tested in a pilot study with approximately 400
probands. For all assessments, SOPs were established by
teams of at least one epidemiologist and one clinical
expert. Adherence to SOPs was reviewed by appointed
internal supervisors in regular intervals. The conduct of
the assessment programmes was audited by external
experts. All staff members underwent extensive training
before conducting assessments. After data collection, data
were checked regularly for completeness, plausibility and
consistency using pre-defined algorithms. Furthermore,
data were monitored statistically at the population level
in order to detect deviations from SOP adherence or
malfunctions of medical devices.
Assessment programme
The assessment programme comprised physical and med-
ical examinations (Table 2), computer-assisted personal
interviews, computer- or paper-based self-administered
questionnaires, psychometric tests (Table 3), and clinical
chemistry from blood and urine samples (Table 4).
All study participants underwent a core assessment
programme with an average duration of 5-6 h within one
day (‘core programme’). Participants aged ≥65 years
(≥60 years and above since March 2013) were invited to
take part in two additional assessment programmes, which
were scheduled shortly after the core programme visit on
two separate days with an average duration of 3-4 h each.
One of these additional programmes focussed on cogni-
tive function and a MRI scan of the brain (‘cognition
programme’). The second additional programme was ded-
icated to detailed assessment of depressive symptoms and
vigilance including multi-paradigm EEG (‘depression
programme’).
Physical and medical examinations
Anthropometry
Only few anthropometric measures (e.g. body height,
weight, waist, and hip) are usually obtained in epidemio-
logical studies. It was our objective to investigate the
potential of 3D body scanning technology to identify novel
phenotypic anthropometric traits. Body scans of all
participants were obtained using a laser-based 3D body
scanner (Anthroscan VITUS SMART XXL with software
ScanWorX 2.9.9b, Human Solutions) with 3 mm vertical
and 1 mm horizontal resolution at 27 measurement points
per square centimetre body surface. An initial set of about
150 length and circumference measures was computed
from each scan.
Classical anthropometric measurements were also
taken, according to standardized procedures by trained
study nurses. Body weight was measured with an elec-
tronic scale (SECA 701, Seca Gmbh & Co KG) with a
precision of 0.01 kg. Body height was assessed by means
of a stadiometer (SECA 240) to the nearest 0.1 cm.
Waist, hip, upper arm, thigh and calf circumferences were
taken using an ergonomic circumference measuring tape
(SECA 201) to the nearest 0.1 cm.
A subcohort of 1200 participants across all age groups
was invited to undergo abdominal MRI in order to quantify
visceral and subcutaneous adipose tissue volumes. The ab-
dominal MRI scan covered the abdominal region starting
10 cm proximal and ending 10 cm distal from the umbil-
icus with a layer thickness of 1 cm. Semi-automated image
segmentation was used to separate subcutaneous from
visceral adipose tissues and to obtain volumetric data.
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Heart function
It was our objective to obtain a deep phenotyping of the
heart function to investigate various modes of heart fail-
ure and valve dysfunction and link this to coronary heart
disease, carotid atherosclerosis and to vascular dementia
in elderly participants. The aim was to identify and to
follow subjects with first signs of reduced cardiac pump
function. For this purpose cardiac ultrasound examination
was performed using the GE Vivid 7 dimension BTO8
echocardiography station (GE Healthcare). Echocardiog-
raphy was conducted by 3 study nurses, who were exten-
sively trained for two months by a supervisor-sonographer
with European certification. The assessment protocol
lasted 20 min and included parasternal, apical, and
subcostal views with 2D and apical view with 3D probes
carefully described in an extensive SOP. In total, 17
sweeps were conducted in a highly standardized way and
28 images were taken (1 along parasternal axis, 7 in
parasternal short axis, 8 in apical long axis including PW-
and CW Doppler, TVI and TDI, 2 in apical 2 chamber
view with TDI, 6 in apical 4 chamber view including TVI
and TDI, 1 subcostal view, 3 other apical views). Standard-
ized reading of the echocardiographic assessments was
performed according to ASE recommendations and the
European Society of Cardiology by means of the software
EchoPAC Version 113 (GE Healthcare). Readings were
performed by the sonographers and a trained reader.
Structural parameters include ventricular, septal, and
posterior wall thickness and left atrial and ventricular
dimensions, which are used to calculate left ventricular
volumes and mass, left ventricular ejection fraction, left
atrial volume, and left atrial function. Readings were
performed according to ASE recommendations and the
European Society of Cardiology. Regarding diastolic
dysfunction and heart failure, our method permitted to
calculate the diastolic state by the assessment described by
Nagueh et al. and Paulus et al [11, 12]. Analysis of the car-
diac valves was performed according to the international
guidelines by conventional 2D as well as color coded and
Doppler echocardiography.
To investigate cardiac arrhythmias a 10-second 12-lead
electrocardiogram (ECG) was recorded using the Page-
Writer TC50® ECG system (Philips Medical Systems) after
a supine resting period of at least 10 min. The ECG was
evaluated by means of the software ECGVue C.03.01.02
(Philips Medical Systems) based on published criteria with
particular focus on rhythm and conduction disturbances,
ST-segment and J-point changes, T and U waves, PQ and
QT interval, hypertrophy, and QRS morphology [13–19].
Vascular system
It was a major objective to investigate and to follow early
signs of atherosclerosis using extensive phenotyping of
the vascular system. Blood pressure was measured three
times at 3-min intervals using an automatic oscillometric
blood pressure monitor (OMRON 705IT, OMRON
Medizintechnik Handelsgesellschaft mbH) after resting
for at least 5 min.
Using the same ultrasound device as for heart ultra-
sound, carotid artery sonography for atherosclerotic
plaques and intima media thickness of the arterial wall
were assessed in all participants. Atherosclerotic plaque of
the carotid artery was defined according to the ‘American
Society of Echocardiography Carotid Intima-Media Thick-
ness Task Force’ as an echogenic thickening of intimal
reflection that extends into the arterial lumen at least
0.5 mm or 50 % of the surrounding intima media thick-
ness (IMT) of the common carotid artery (CCA) or an
intimal plus medial thickness of >1.5 mm [20]. Assess-
ment of central arterial stiffness and vascular aging was
performed by non-invasive measurements of pulse-wave
velocity (PWV), pulse wave analysis (PWA), augmentation
Table 2 Physical and medical examinations
Examination Sample size
Bio-specimen asservation
Serum, plasma, lymphocytes for DNA, RNA, urine >9900
Anthropometry
Classical: Body weight, body height,
circumference measures
>9900
3D laser based optical body surface scan >9800
MRI based abdominal fat tissue volumetry >1000
Cardiovascular system
Blood pressure >9900
Electrocardiography (10 s, 12 leads) >9700
Echocardiography >8300
Carotid ultrasound >9600




Oral glucose tolerance test (OGTT) >2900
Physical activity and fitness
Hand grip strength >9700
7 day actimetry >2800
Eye





Electroencephalography (≥60 years only) >3000
Miscellaneous
Voice profile >2700
Olfactory test (Sniffin’ sticks 12) >7300
Skin prick test (six inhalative allergens) >8000
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index, and the ankle-brachial index (ABI) using oscillome-
try-, and photoplethysmography-based methods (Vicorder,
Skidmore medical, UK).
Oral glucose tolerance test (OGTT)
It was our objective to determine the prevalence of
unrecognized diabetes, to better understand mechanisms
of insulin resistance, and to define a subcohort of predi-
abetic participants for future follow up. The OGTT test
was conducted in all fasted participants who came to the
study centre before 8 a.m. After initial blood drawing
and an intake of 75 g of glucose solution (Accu-Chek®
Dextrose O.G.T. Saft, Roche Diagnostics Deutschland
Table 3 Computer- assisted personal interviews (I),
self-administered questionnaires (Q) and cognitive tests (T)
Assessment Type Target population
(age)




Medical history I 18-79
Family medical history I 18-79
Medication (last 7 days) I 18-79
Allergies I 18-79
Male and female gender questions Q 18-79
Immune competence Q 18-79
Oral health Q 18-79
Life style
Smoking I/Q 18-79
Food frequency and alcohol consumption Q 18-79
International Physical Activity Questionnaire
(IPAQ)
Q 18-79
Three-Factor-Eating Questionnaire (TFEQ) Q 18-79
Yale Food Scale Q 18-79
Psychosocial aspects
Satisfaction with Life Scale (SWLS) Q 18-79
Generalized Anxiety Disorder (GAD-7) Q 18-79
Patient Health Questionnaire (PHQ-15) Q 18-79
SF-8 Health Survey Q 18-79
Life Orientation Test Revised (LOT-R) Q 18-79
ENRICHD Social Support Instrument (ESSI) Q 18-79
Personality Adjective List (16 AM) Q 18-79
Lubben Social Network Scale (LSNS) Q 18-79
EuroQol visual analogue scale (EQ VAS) Q 18-79
Sense of Coherence Leipzig Short Scale
(SOC-L9)
Q 18-79
Childhood Trauma Screener (CTS) Q 18-79
Use of health care services Q 18-79
Barratt’s Impulsivity Scale Version 11 (BIS-11) Q 18-79
Behavioral inhibition system / behavioral
activation system (BIS/BAS)
Q 18-79
NEO-Five-Factor Inventory (NEO-FFI-30) Q 18-79
Need Inventory of Sensation Seeking (NISS) Q 60-79
Hypomanic Personality Scale Q 60-79
Sleep
Pittsburgh Sleep Quality Index (PSQI) Q 18-79
Multidimensional Fatigue Inventory (MFI-20) Q 18-79




Sleep Questionnaire (SF-A) Q 60-79
Table 3 Computer- assisted personal interviews (I),
self-administered questionnaires (Q) and cognitive tests (T)
(Continued)
Cognition
Stroop test T 18-79
Trail-Making Test A&B T 18-79
Subjective Memory Impairment I 18-79
Verbal Fluency Test ‘Animals’ T 18-79
Behavioral Assessment of the dysexecutive
syndrome (DEX)
Q 18-79
Triangle test T 60-79
Reading the mind in the eyes test T 60-79
Structured Interview for Diagnosis of
Dementia of Alzheimer type, Multi-infarct
Dementia and Dementia of other Aetiology
according to DSM-III-R, DSM-IV and ICD-10
I/T 60-79
Barthel-Index for basic Activities of
Daily Living
I 60-79
Instrumental Activities of Daily Living
Scales (IADL)
I 60-79
CERADplus neuropsychological test battery T 60-79
Wechsler Memory Scale T 60-79
Iowa gambling task T 18-79a
n-back task T 18-79a
Reversal learning task T 18-79a
Depression
Centre of Epidemiologic
Studies - Depression Scale (CES-D)
Q 18-79
Childhood Trauma Questionnaire (CTQ) Q 18-79
CIDI-DIA-X Screener Q 18-79
Structured Clinical Interview for DSM
Disorders (SCID)
I 60-79
Geriatric Depression Scale (15-item version,
GDS-15)
Q 60-79
Inventory of Complicated Grief (ICG) Q 60-79
Inventory of Depressive Symptoms (IDS-SR) Q 60-79
Leipzig Life Event List Q 60-79
aOnly for the subgroup with additional obesity assessments
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GmbH), blood samples were taken for measurement of
glucose and insulin concentration at 30 (glucose only)
and 120 min.
Physical activity, fitness, and sleep patterns
Physical activity and sleep patterns are associated with
health and hence were assessed quantitatively. Physical
activity and sleep-wake regulation were objectively mea-
sured using a 2D-axial accelerometer. The SenseWear
Pro 3 device (Bodymedia, Inc., Pittsburgh, PA) allowed
recording of skin temperature, near body ambient
temperature, heat flux, galvanic skin response, and mo-
tion. It is particularly useful for recording objective sleep
duration. Participants were requested to wear the device
continuously for 7 days and to keep a sleep and activity
diary. Raw data were processed using the SenseWear
Professional software to detect wake and sleep periods
and to classify the time spent in low, moderate or vigor-
ous physical activity, daily step counts and energy ex-
penditure in MET-minutes. Maximal grip strength was
assessed as the maximum of 6 alternate measurements
of the right and the left hand using the Jamar dynamom-
eter (Patterson Medical Ltd., Huthwaite, UK) [21].
Ophthalmological imaging
Degeneration of the macula and glaucoma are major age-
related disorders associated with considerable handicap. It
was our objective to unravel early signs of these disorders
and follow them up longitudinally. In-vivo ophthalmo-
logical imaging techniques using OCT enabled sensitive
detection of abnormalities. OCT is a medical diagnostic
imaging technique which captures micron resolution 3-
dimensional images. It is based on the principle of optical
reflectometry. We employed OCT (Heidelberg Spectralis
SD-OCT) and high quality non-mydriatic fundus imaging
(Nidek AFC-230) to produce representative images of the
retina and optic nerve. All images were read by two inde-
pendent observers who classified degenerative changes and
anomalies based on current ophthalmological standards.
Neuroimaging and neurocognitive assessments
Neurocognitive disorders are progressing particularly in
the elderly. It was our objective to investigate early signs
of neurodegeneration and of small vessel disease and
their neurocognitive correlates. In addition we were in-
terested whether obesity is mirrored in brain structures
and functions. To obtain a structural and functional
MRI assessment of the brain the following magnetic res-
onance pulse sequences were applied: i) Magnetization
prepared rapid gradient echo using a 3D T1-weighted
pulse sequence in order to assess brain structure and to
highlight differences between grey and white matter.
Based on these data, voxel-based morphometry and cor-
tical thickness measurements were performed. ii) Diffu-
sion weighted imaging at 60 different angles using pulse
sequences, which are sensitive to water diffusion and its
direction. Based on this information, parameters charac-
terizing white matter such as various characteristics of the
diffusion tensor (axial, radial diffusivity, fractional anisot-
ropy etc.) were determined. iii) Resting state functional
MRI. Here, oxygenation changes were investigated during
rest as a measure for functional connectivity. iv) Fluid-
attenuated inversion recovery, which is highly sensitive for
the identification of white matter lesions. v) Susceptibility
weighted imaging using a T2*-weighted pulse sequence,
which is highly sensitive to brain hemorrhage. vi) MR-
angiography, which was used for the assessment of arterial
brain vessels, e.g. to identify aneurysms.
Structural and functional MRI parameters were used to
identify specific neurodegenerative diseases and its pre-
stages, subjective and mild cognitive impairment. For Alz-
heimer’s disease we focussed on atrophy in hippocampal
regions and connectivity changes in temporoparietal brain
networks, for subtypes of frontotemporal lobar degener-
ation on changes in structure and function of respective
Table 4 Laboratory analyses
Parameter
Electrolytes: Sodium, Potassium, Chloride, Magnesium
Liver and pancreas: Alanine transaminase, Aspartate transaminase,
Choline esterase, Gamma-glutamyltransferase, Bilirubin (total and direct),
Lipase, Total protein, Albumin, Urea
Kidney: Creatinine, Cystatin C
Cardiac markers: Creatine kinase, Creatine kinase MB, Myoglobin,
Troponine T high sensitive, N-terminal prohormone of brain
natriuretic peptide
Lipid metabolism: Cholesterol, High density lipoprotein cholesterol,
Low density lipoprotein cholesterol, Apolipoprotein B, Apolipoprotein
A1, Trigycerides, Lipoprotein (a)
Glucose metabolism: Glucose, Insulin, C-peptide, Glycated
hemoglobin (HbA1c)
Iron metabolism: Transferrin, Ferritin
Vitamins: Folic acid, Vitamin B12
Bone metabolism: Alkaline phosphatase, Phosphate, Calcium,
Osteocalcine, Beta-CrossLaps, Propeptide of type I collagen,
Parathormone, 25-Hydroxy vitamin D3
Endocrine function / hormones: Cortisol, Luteinizing hormone, Follicle
stimulating hormone, Estradiol, Testosterone, Sex hormone-binding
globulin, Dehydroepiandrosterone sulfate
Thyroid: Thyrotropin (TSH), Free triiodothyronine, Free thyroxine, TSH
receptor antibodies, thyroglobulin antibodies, Thyreoperoxidase
antibodies
Inflammatory mediators: Interleukin 6, C-reactive protein high sensitive
Allergy diagnostics: specific immunoglobulin E sx1 (timothy grass,
rye, birch, mugwort, C. herbarum, D. pteronyssinus, cat, dog), fx5
(hen’s egg, cow’s milk, fish, wheat, peanut, soy), total immunoglobulin E
Hematology: Complete blood cell count with differential, Reticulocytes
Urine: Albumin, Creatinine, Immunoglobulin G
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brain regions, for vascular diseases such as small vessel
diseases on automatic detection of white matter lesions
and changes in connectivity measures [22–25].
Electroencephalography
The onset of depression is believed to be linked to a dys-
regulation of the sleep-wake rhythm and a disturbance of
vigilance regulation. According to the vigilance model of
affective disorders put forward by Hegerl et al. [26] hyper-
stable vigilance regulation is associated with depressive
disorders whereas unstable vigilance regulation is associ-
ated with disorders such as Attention Deficit/Hyperactiv-
ity Disorder or (hypo)manic states. To investigate this
hypothesis for the first time in a large population-based
cohort elderly participants underwent an EEG comprising
of 3 paradigms: A 20-min resting EEG was performed to
quantify wakefulness (EEG-vigilance) regulation according
to the Leipzig Vigilance Algorithm Protocol (VIGALL,
http://uni-leipzig.de/~vigall/). Furthermore, evoked poten-
tials were assessed using a 15 min Novelty-Oddball-
Paradigm (P300), and a 15 min Intensity Dependence of
Auditory Evoked Potentials paradigm [27, 28]. Alterations
in P300-amplitude and latency have been linked to neuro-
degenerative processes and IAEP-magnitude has been
linked to serotonin levels in the brain [28, 29]. All EEG re-
cordings were performed by trained staff in an electrically
shielded and sound attenuated EEG booth using a
31-channel EEG (QuickAmp, Brain Products GmbH).
Instructions were standardized using presentation scripts
(Presentation Software).
Voice function
The voice is a highly individual part of the human per-
sonality and a base of speech development and commu-
nication. It was our objective to phenotype the human
voice by standardized voice limit measurements (fre-
quency dependent sound-pressure levels) when speaking
and singing. This provides a profile of the volume and
pitch range of a voice [30]. Profiling was undertaken as a
novel phenotype assessment in an epidemiological
setting. So far only twin studies are available [31]. The
speaking voice is examined from quietest speaking over
two raised loudness levels up to shouting while continu-
ously counting. A microphone was attached to a headset
at a distance of 30 cm from the mouth (DiVAS® device,
XION medical, Berlin, Germany). The measurement of
the singing voice included softest and loudest singing,
each beginning in mean fundamental frequency of
speaking, then singing stepwise down to the lowest and
up to the highest frequency. The measurement values
and their registration are displayed as a speaking and a
singing voice profile. An acoustic analysis (real-time
spectrum) for each individual tone provided additional
information about the resonance quality of the voice.
Olfactory test
Epidemiological data on the olfactory function in larger
and representative samples of the general population are
scarce. It was our objective to investigate whether olfac-
tory function is an early indicator for neurodegeneration
and possibly cognitive impairment. In order to assess the
ability to identify different odours, the Burghart Sniffin’
Sticks “Screening12 Test” (Burghart Messtechnik GmbH,
Wedel, Germany) was applied using 12 felt-tip pens. The
odours of these sticks were peppermint, fish, coffee,
banana, orange, rose, lemon, pineapple, cinnamon, cloves,
leather and liquorice. Participants were asked to name the
odour as a forced choice out of four possible answers, only
one of which was correct.
Allergy test
It was our objective to investigate allergy prevalence in
adult patients of advanced age and to investigate asso-
ciations with immunological signals in the blood.
Subjects of all age groups underwent skin prick test
(ALK-Abello, Hamburg, Germany) with positive/nega-
tive control, birch, timothy grass, mugwort, ragweed,
alternaria, and Dermatophagoides pteronyssinus. Reading
was performed after 15 min either by ruler measurement
or by a three dimensional imaging system (Primos-Pico,
Fa. GFMesstechnik, Teltow; software from red.soft it-
service GmbH Oberpullendorf, Austria) [32, 33]. Further-
more, measurement of IgE was performed (total/sx1: tim-
othy grass, rye, mugwort, birch, Cladosporium herbarum,
Dermatophagoides pternonyssinus, cat, dog/fx5: hen’s egg,
cow’s milk, codfish, wheat flour, peanut, soy).
Interviews, questionnaires, and cognitive tests
Socio-economic status
Data on socio-economic and socio-demographic factors
were obtained in a structured interview. A multidimen-
sional index was calculated from information on education
(school, professional), occupational status, and equivalent
household income [34, 35].
Medical history, family history, and medication
Participants were interviewed about medical diagnoses
that were previously confirmed by a physician, including
age at first diagnosis, whether symptoms were present in
the past 12 months, and whether the disease was cur-
rently under treatment. The interview comprised over
70 common diseases. In addition, participants were
interviewed about diseases in their first degree relatives.
Data on medications and dietary supplements taken
within the last 7 days before the core programme visit
were gathered. Medication was identified by bar codes
scanned from the original packaging presented by the
participants. For data analysis, all medications were
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coded by the active agents using the Anatomical Thera-
peutic Chemical classification system.
Lifestyle and diet
The tobacco assessment contained questions on ever and
current smoking, duration of smoking, amounts of differ-
ent tobacco products, and exposure to passive smoking.
Alcohol consumption was assessed with regard to fre-
quency and amount of different alcoholic beverages con-
sumed within the last year, as well as on alcohol abuse in
the past. Regarding dietary patterns, participants were
asked about the consumption frequency of 34 food groups
and 13 types of beverages within the last 12 months.
Questions related to the vegetarian diet, meals and body
weight were asked. Specific aspects of eating behaviour
such as cognitive restraint, disinhibition, and hunger as
well as the frequency of common difficulties in eating behav-
iour in the general population (e.g. craving for sweets, eat-
ing in response to stress) were assessed using the German
version of the Three-Factor-Eating Questionnaire [36].
Subjectively reported physical activity was assessed using
the short form of the International Physical Activity Ques-
tionnaire (IPAQ-SF, https://sites.google.com/site/theipaq/).
Cognitive performance
To assess the prevalence of cognitive impairment, to in-
vestigate putative risk and protective factors of dementia
and corresponding pre-stages such as subjective memory
impairment and mild cognitive impairment, and to
analyze general cognitive functioning in the population.
Several subjective and objective cognitive performance as-
sessments were examined in all participants. Subjective
cognitive performance was assessed via a structured
15-item interview. Objective cognitive performance was
assessed using – amongst others – the Trail-Making Test
A & B and the Verbal Fluency Test ‘Animals’, which are
subtests of the CERADplus test battery (extended neuro-
psychological test battery of the Consortium to Establish a
Registry for Alzheimer’s Disease) [37, 38]. Elderly partici-
pants underwent an additional deep and comprehensive
cognitive assessment programme on a separate day (cog-
nition programme) together with a brain MRI-scan. The
programme included, for example, all the further subtests
of the CERADplus test battery as well as the SIDAM
(Structured Interview for Diagnosis of Dementia of
Alzheimer type, Multi-infarct Dementia and Dementia of
other Aetiology according to DSM-III-R, DSM-IV and
ICD-10) [39]. Impairments in daily activities were assessed
via the Barthel-Index (basic activities) and the Instrumen-
tal Activities of Daily Living Scale (IADL) [40, 41].
Depressive symptoms
Depressive symptoms are the most common mental symp-
toms in the population. The seriousness of depressive
symptoms becomes apparent in the burden that comes
along with such symptoms including incapacity to work
and high health care costs. Our objective was to determine
the prevalence of depressive symptoms in the general
population and to identify subgroups that are especially
vulnerable to suffer from depressive symptoms. Depressive
symptoms were assessed in all probands using the German
version of the Centre of Epidemiological Depression Scale
(CES-D) screening instrument [42, 43]. In the elderly sub-
group, a more detailed assessment of depressive symptoms
was performed (depression programme). Additional self-
ratings were taken using the Inventory of Depressive
Symptoms (IDS-SR) and the Geriatric Depression Scale
(GDS-15) [44, 45]. In all elderly persons the diagnosis of
psychiatric illnesses was assessed using the Structured
clinical interview for DSM-IV (SCID-I) [46].
Psychosocial aspects, life satisfaction, stressors
It was our objective to determine the impact of psycho-
social factors and personality profiles on multiple health
conditions. In addition we aimed to derive new normative
values of the general population for novel instruments,
based on a large community-based sample, and to investi-
gate the relationship between quality of life, psychosocial
factors, socio-demographic variables, and health behav-
iour. We therefore applied a broad battery of self-reported
assessments including instruments measuring quality of
life, personality, and several psychosocial factors. In par-
ticular, the following questionnaires were used: The Short
Form 8 (SF-8) measuring health-related quality of life
[47], the Generalized Anxiety Disorder questionnaire
(GAD-7) [48], the Patient Health Questionnaire-15 (PHQ-
15), measuring bodily complaints [49], the ENRICHD
Social Support Scale (ESSI) [50], the Life Orientation
Test – revised (LOT-R), measuring dispositional optimism
[51], the Satisfaction With Life Scale (SWLS) [52], the
Personality Adjective List (16-AM), measuring personality
traits according to the Big Five [53], the Lubben Social
Network Scale (LSNS) [54], the EuroQol visual analogue
scale (EQ VAS) [55], the Sense of Coherence Leipzig Short
Scale (SOC-L9) measuring a global orientation to view the
world and the individual environment [56], and a short
form of the Childhood Trauma Questionnaire (CTQ) –
the Childhood Trauma Screener (CTS) – as a scale for
the retrospective assessment of childhood abuse and
neglect experiences [57, 58].
Sleep and sleepiness
It was our objective to investigate the role of sleep duration
(see above) and sleep quality for somatic and mental
health. A short sleep duration is associated with weight in-
crease, obesity, diabetes type 2, hypertension, and overall
increased morbidity and mortality [59–66]. Sleep problems
are also closely associated with psychiatric conditions,
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especially affective disorders [67–71]. All participants were
asked to evaluate their sleep quality and other sleep-related
aspects using standardized questionnaires: e.g. the
Pittsburgh Sleep Quality Index (PSQI) [72], and the
Epworth Sleepiness Scale (ESS) [73] (for details see Table 4).
Laboratory measurements
It was our objective to unravel and to validate laboratory
biomarkers significantly associated with disease pheno-
types and risks. An extensive panel of laboratory tests cov-
ering 83 analytes and biomarkers (clinical chemistry,
hematology, immunology, endocrinology and metabolism)
was performed on fresh biospecimen directly on the day
of sample collection in a highly standardized manner
(Table 4). It is a major goal to investigate and to identify
novel genetic modifiers of phenotypes and disease risk.
To this end, we aimed to genotype all participants using
the Affymetrix AXIOM-CEU genome-wide SNP array,
addressing a total of 587,352 variants. Genotyping was
accompanied by genome-wide gene expression analyses
for the whole blood, which was collected in Tempus Blood
RNA Tubes (Life Technologies) and transferred to -80 °C
prior to further processing. Isolated RNA was processed
and hybridised to Illumina HT-12 v4 Expression Bead-
Chips (Illumina, San Diego, CA, USA) and scanned on
the Illumina HiScan. We investigated the association of
metabolic biomarkers (quantitiative tandem mass spec-
trometry: amino acidy, fatty acid oxidation, steroids, ste-
rols, eicosanoids, phospholipids, tri- and diacylglycerols,
apolipoproteins and others) with major disease
phenotypes, the genome and other biomarkers. For the
whole blood analysis of 26 amino acids, free carnitine and
34 acylcarnitines, 40 μl of native EDTA whole blood
were spotted on filter paper WS 903 (GE Healthcare,
Germany). Dried blood spots were stored at -80 °C after
3 h of drying until batch analysis. Sample pretreatment
and measurement are described in detail elsewhere
[74, 75]. Analyses were performed on an API 2000 and
API 4000 tandem mass spectrometer (Applied Biosystems,
Germany). Quantification was performed using Chemo-
View™ 1.4.2 software (Applied Biosystems, Germany).
In a subcohort of over 900 participants comprising all
age groups, a detailed leukocyte subtype phenotyping
with an extensive antibody panel was performed from
EDTA whole blood samples using 10 colour flow cytom-
etry (Navios flow cytometer, Beckman Coulter, Pasadena,
CA, USA) [76, 77].
Discussion
Before the main study recruitment started we had
undertaken a series of feasibility studies to investigate
the suitability of assessment procedures and to define
SOPs. We then defined the parcours of all assessments
and conducted a full pilot study with 400 volunteer
participants. This helped us to optimize the logistics and
the timing of the main study.
Recruitment for the main study started in August
2011 and ended in November 2014 when the planned
sample size of 10,000 participants was reached. During
the first 13 months of the recruitment phase, the study
centre was located in a provisional building with limited
space. Therefore, recruitment was restricted to 8-10 par-
ticipants per day. In September 2012 the study site
moved to a more spacious and reconstructed building
and recruitment could be increased to 18-20 participants
per day (7 am to 4.30 pm, Monday to Friday). Once per
month the study centre was in operation on Saturday in
order to allow participation of individuals who were not
able to attend on a weekday. Assessments were performed
by trained study nurses and interviewers. One staff mem-
ber was responsible for quality management. Participants
were informed about the the assessment programme by
watching a video, which was shown in the waiting area.
The study programme attracted high public attention.
Recruitment was accompanied by reports in local newspa-
pers and on local television to increase awareness. A
website was established with information and video
trailers (http://life.uni-leipzig.de). There were annual press
releases with status reports. several open days were orga-
nised, which were well attended. Among all invited
citizens from the city of Leipzig aged 40 or older, 33 % did
actively participate, 30 % declined to participate, and 37 %
did not respond despite a reminder letter. Efforts were
undertaken to obtain telephone numbers and to contact
non-responders by telephone. However, telephone num-
bers for only 25 % of non-responders could be retrieved
from publicly available telephone directories. Of these,
only 18 % finally agreed to participate, contributing 4 % of
the response rate.
The core assessment programme was planned to last
5-6 h. Except for some of the above mentioned elderly
participants over the age of 75, almost all participants
successfully completed the entire assessment programme
as planned. A few physical and medical assessments
were performed only in subsamples due to logistic
reasons (e.g., oGTT tests were only conducted in partici-
pants scheduled in the morning before 8 a.m.) or
because they were added to the assessment programme
at a later phase during the study (see Table 3 for details).
An evaluation of a questionnaire on participants’ satis-
faction with the study showed that 96.0 % of the partici-
pants were very satisfied or satisfied. A total of 88.5 %
stated that they would do the assessment again and that
they would recommend it to other participants. Only
1.8 % of the participants stated that they would not
participate again. Compliance with the extended
cognition and depression programmes for the elderly
participants was also high.
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No participant showed a severe pathological finding that
would have required immediate intervention. Fifteen par-
ticipants had findings that were not acute life-threatening
but required immediate medical clarification or treatment.
Furthermore, 116 participants were informed by the study
centre to seek for near-term medical clarification based on
pathological measurement results.
For MRI assessments, very strict inclusion and exclu-
sion criteria applied. One exclusion criterion was the
presence of skin tattoos due to the potential risk of cuta-
neous burns due to ferromagnetic compounds in tattoo
pigments. We observed a high prevalence of skin tattoos
in persons below 40 years (approximately 50 %). This
decreased the participation rate in the younger obesity
sub-cohort remarkably.
The LIFE-Adult-Study is so far the largest population-
based study of urban individuals with such extensive
phenotyping conducted in Germany. It is building on
the experience of other population studies which have
been conducted in Germany in the past, such as the
KORA, SHIP, CARLA and Heinz-Nixdorf-Recall studies
[2–6]. In the design and implementation phase of the
LIFE-Adult-Study extensive interactions and support
from these German study teams helped to define the
comparability of the assessments and SOPs. Principle in-
vestigators of these studies are members of the scientific
advisory board of LIFE.
A particular strength of the LIFE-Adult-Study is the
deep and innovative phenotyping in several fields of
interest strongly supported by researchers from the
Medical Faculty of the University of Leipzig. A particular
objective in the field of neurodegenerative diseases is the
multidimensional assessment of mild cognitive impair-
ment, which often is a pre-stage of clinical manifest de-
mentia. This is investigated by multiple cognitive tests
complemented by a high resolution 3 T-MRI scan re-
garding brain morphology, resting state and DTI. An-
other objective of particular concern is the deep
assessment of depressive symptoms and whether they
relate to clinically diagnosed manifest depression as
measured by the SCID instrument. To investigate the
link to sleep-wake regulation this is accompanied by inves-
tigations of sleep quality and rhythm and an EEG-based
paradigm assessment of vigilance regulation. Metabolic
disorders relating to glucose and lipid metabolism, and as-
sociated diseases like obesity and the metabolic syndromes
are another major interest in the LIFE-Adult-Study. This
led us to undertake extensive laboratory investigations in-
cluding metabolic and extensive heart and vascular exami-
nations notably with regard to atherosclerotic phenotypes.
In addition, participants were asked for social isolation, life
style and quality of life. For the first time in an epidemio-
logical setting, we used 3D body scans to assess body
shapes which permits to define novel anthropometric
phenotypes in much greater detail than classical anthro-
pometry is able to provide. Particular attention is paid to
early degenerative changes of the retina and the optic
nerve region. We performed one of the first population
based assessment employing OCT to unravel early-onset
lesions of the retina.
At present we have started the data curation
process of the entire cohort database. We are per-
forming and completing the reading of the signal and
image based data (e.g. MRI-scans, EEG-scans, ECG-
recordings, OCT-images, heart ultrasound, carotis
examination, voice profiles and accelerometer read-
outs). A first wave of SNP-based genotyping of 4500
participants will be available soon. We expect to have
prevalence estimates of major clinical and subclinical
phenotypes by autumn 2015.
The LIFE-Adult-Study is designed as a longitudinal co-
hort study. Based on a first interim analysis of 4300 partici-
pants in 2013 we can project a conservative calculation on
expected incident cases. At a follow-up after 4 years we ex-
pect numerous newly diagnosed events such as diabetes
(~200 cases), hypertension requiring treatment (~500
cases), severe heart failure (~300), participants with vascu-
lar alterations in the carotids (~500), pathological macula
lesion (~150), cutaneous allergies (~300), and dementia
(~80). Based on the data from all 10,000 participants we
will design details of the first longitudial follow-up sched-
uled to start in 2016.
The LIFE Centre for Civilization Diseases is also
conducting other cohort and patient studies. The LIFE-
Child-Study is currently recruiting a neonate sub-
cohort and a population based cohort of children and
adolescents in an age range from 3-18 years. This study
is recalling participants in a narrow time frame of 1-2
years [78]. The LIFE-Heart-Study is a clinical cohort of
heart patients with clinical indication for coronary angi-
ography. It consists of a large subcohort of patients
with first initial angiography of the coronary arteries
and a subcohort of acute myocardial infarction survi-
vors [79]. All patients of the LIFE-Heart-Study are
recruited (7000 participants). The study belongs to
the largest fully genotyped studies worldwide with
angiographically assessed coronary patients. The LIFE-
Heart-Study is a collaborating member of large inter-
national networks for genome metanalysis (Cardiogram,
Genius). Since 2014 the LIFE study centre is presently
recruiting new participants as a regional study site of
the German National Cohort, which has recently
started and aims to set a nationwide cohort of 200,000
individuals [80].
Here we have reported about the design of the study
to provide the community with this information, to fa-
cilitate subsequent forthcoming publications and reach
potential future cooperation partners.
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